C-type natriuretic peptide in prostate cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

C-type natriuretic peptide in prostate cancer. / Nielsen, Soeren Junge; Iversen, Peter; Rehfeld, Jens F.; Jensen, Helle Lone; Goetze, Jens Peter.

I: Acta Pathologica Microbiologica et Immunologica Scandinavica, Bind 117, Nr. 1, 01.01.2009, s. 60-7.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Nielsen, SJ, Iversen, P, Rehfeld, JF, Jensen, HL & Goetze, JP 2009, 'C-type natriuretic peptide in prostate cancer', Acta Pathologica Microbiologica et Immunologica Scandinavica, bind 117, nr. 1, s. 60-7. https://doi.org/10.1111/j.1600-0463.2008.00016.x

APA

Nielsen, S. J., Iversen, P., Rehfeld, J. F., Jensen, H. L., & Goetze, J. P. (2009). C-type natriuretic peptide in prostate cancer. Acta Pathologica Microbiologica et Immunologica Scandinavica, 117(1), 60-7. https://doi.org/10.1111/j.1600-0463.2008.00016.x

Vancouver

Nielsen SJ, Iversen P, Rehfeld JF, Jensen HL, Goetze JP. C-type natriuretic peptide in prostate cancer. Acta Pathologica Microbiologica et Immunologica Scandinavica. 2009 jan 1;117(1):60-7. https://doi.org/10.1111/j.1600-0463.2008.00016.x

Author

Nielsen, Soeren Junge ; Iversen, Peter ; Rehfeld, Jens F. ; Jensen, Helle Lone ; Goetze, Jens Peter. / C-type natriuretic peptide in prostate cancer. I: Acta Pathologica Microbiologica et Immunologica Scandinavica. 2009 ; Bind 117, Nr. 1. s. 60-7.

Bibtex

@article{f022df50590511df928f000ea68e967b,
title = "C-type natriuretic peptide in prostate cancer",
abstract = "C-type natriuretic peptide (CNP) is expressed in the male reproductive organs in pigs. To examine whether the human prostate also expresses the CNP gene, we measured CNP and N-terminal proCNP in prostate cancer tissue extracts and performed immunohistochemical biopsy staining. Additionally, proCNP-derived peptides were quantitated in plasma from patients with prostate cancer. Blood was collected from healthy controls and patients before surgery for localized prostate cancer. Tissue extracts were prepared from tissue biopsies obtained from radical prostatectomy surgery. N-terminal proCNP, proCNP (1-50) and CNP were measured in plasma and tissue extracts. Biopsies were stained for CNP-22 and N-terminal proCNP. Tissue extracts from human prostate cancer contained mostly N-terminal proCNP [median 5.3 pmol/g tissue (range 1.0-12.9)] and less CNP [0.14 pmol/g tissue (0.01-1.34)]. Immunohistochemistry demonstrated the presence of the peptides in prostatic epithelial cells. The N-terminal proCNP concentrations in plasma were marginally lower in patients with localized prostate cancer compared with control subjects [13.8 pmol/l (11.0-17.2) vs. 15.1 pmol/l (10.4-23.2), p=0.002] but not enough to justify the use of N-terminal proCNP as a cancer marker. Further research is needed to establish whether measurement of proCNP-derived peptides may offer clinical information.",
author = "Nielsen, {Soeren Junge} and Peter Iversen and Rehfeld, {Jens F.} and Jensen, {Helle Lone} and Goetze, {Jens Peter}",
year = "2009",
month = "1",
day = "1",
doi = "http://dx.doi.org/10.1111/j.1600-0463.2008.00016.x",
language = "English",
volume = "117",
pages = "60--7",
journal = "A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica",
issn = "0903-4641",
publisher = "Wiley Online",
number = "1",

}

RIS

TY - JOUR

T1 - C-type natriuretic peptide in prostate cancer

AU - Nielsen, Soeren Junge

AU - Iversen, Peter

AU - Rehfeld, Jens F.

AU - Jensen, Helle Lone

AU - Goetze, Jens Peter

PY - 2009/1/1

Y1 - 2009/1/1

N2 - C-type natriuretic peptide (CNP) is expressed in the male reproductive organs in pigs. To examine whether the human prostate also expresses the CNP gene, we measured CNP and N-terminal proCNP in prostate cancer tissue extracts and performed immunohistochemical biopsy staining. Additionally, proCNP-derived peptides were quantitated in plasma from patients with prostate cancer. Blood was collected from healthy controls and patients before surgery for localized prostate cancer. Tissue extracts were prepared from tissue biopsies obtained from radical prostatectomy surgery. N-terminal proCNP, proCNP (1-50) and CNP were measured in plasma and tissue extracts. Biopsies were stained for CNP-22 and N-terminal proCNP. Tissue extracts from human prostate cancer contained mostly N-terminal proCNP [median 5.3 pmol/g tissue (range 1.0-12.9)] and less CNP [0.14 pmol/g tissue (0.01-1.34)]. Immunohistochemistry demonstrated the presence of the peptides in prostatic epithelial cells. The N-terminal proCNP concentrations in plasma were marginally lower in patients with localized prostate cancer compared with control subjects [13.8 pmol/l (11.0-17.2) vs. 15.1 pmol/l (10.4-23.2), p=0.002] but not enough to justify the use of N-terminal proCNP as a cancer marker. Further research is needed to establish whether measurement of proCNP-derived peptides may offer clinical information.

AB - C-type natriuretic peptide (CNP) is expressed in the male reproductive organs in pigs. To examine whether the human prostate also expresses the CNP gene, we measured CNP and N-terminal proCNP in prostate cancer tissue extracts and performed immunohistochemical biopsy staining. Additionally, proCNP-derived peptides were quantitated in plasma from patients with prostate cancer. Blood was collected from healthy controls and patients before surgery for localized prostate cancer. Tissue extracts were prepared from tissue biopsies obtained from radical prostatectomy surgery. N-terminal proCNP, proCNP (1-50) and CNP were measured in plasma and tissue extracts. Biopsies were stained for CNP-22 and N-terminal proCNP. Tissue extracts from human prostate cancer contained mostly N-terminal proCNP [median 5.3 pmol/g tissue (range 1.0-12.9)] and less CNP [0.14 pmol/g tissue (0.01-1.34)]. Immunohistochemistry demonstrated the presence of the peptides in prostatic epithelial cells. The N-terminal proCNP concentrations in plasma were marginally lower in patients with localized prostate cancer compared with control subjects [13.8 pmol/l (11.0-17.2) vs. 15.1 pmol/l (10.4-23.2), p=0.002] but not enough to justify the use of N-terminal proCNP as a cancer marker. Further research is needed to establish whether measurement of proCNP-derived peptides may offer clinical information.

U2 - http://dx.doi.org/10.1111/j.1600-0463.2008.00016.x

DO - http://dx.doi.org/10.1111/j.1600-0463.2008.00016.x

M3 - Journal article

VL - 117

SP - 60

EP - 67

JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

SN - 0903-4641

IS - 1

ER -

ID: 19596534